All Blogs

Feb 22, 2021

Emerging Research Continues To Transform Erythropoietic Protoporphyria Market Outlook


Feb 19, 2021

Hypofibrinogenemia Market: Limited Pipeline Therapies, Abundant Opportunities


Feb 18, 2021

Bluebird suspends gene therapy trials; Cortexyme tripped up by FDA hold; Guardant Health launches surveillance blood test; Enhertu scores approval


Feb 17, 2021

Healthcare in 2021: Top Disruptions Bound To Impact The Way Healthcare Is Delivered


Feb 16, 2021

Merck, Eisai in renal cancer market; G1 Therapeutics on Cosela’s approval; Takeda’s Maribavir; Astellas/Seagen Padcev


Feb 15, 2021

The Paradox of Rare: Chalking out Challenges in the Rare Disease Market


Feb 12, 2021

Limited Therapies in the Rare Disease Pipeline: Watch out for Rare Indications that Calls Out for Novel Therapies


Feb 11, 2021

Verily – Janssen collaboration; Enhancing the response in pancreatic cancer; Avrobio gene therapy eradicates toxic substrate; Gut microbiome responsible for Multiple Sclerosis


Jul 16, 2025

Progeria: The Rarest Case of Premature Ageing


Feb 09, 2021

Deerfield/ Dana-Farber’s USD 130 Million Cancer Research Deal; FDA-Approval to BMS’ Breyanzi & TG Therapeutics’ Ukoniq; EU Marketing Rights for ViiV Healthcare’s Rukobia